Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
Involvement of the FOXO6 transcriptional factor in breast carcinogenesis.

Oncotarget

Lallemand F, Petitalot A, Vacher S, de Koning L, Taouis K, Lopez BS, Zinn-Justin S, Dalla-Venezia N, Chemlali W, Schnitzler A, Lidereau R, Bieche I, Caputo SM.
PMID: 29484124
Oncotarget. 2017 Dec 30;9(7):7464-7475. doi: 10.18632/oncotarget.23779. eCollection 2018 Jan 26.

In mammals, FOXO transcriptional factors form a family of four members (FOXO1, 3, 4, and 6) involved in the modulation proliferation, apoptosis, and carcinogenesis. The role of the FOXO family in breast cancer remains poorly elucidated. According to the...

Cite
Lallemand F, Petitalot A, Vacher S, et al. Involvement of the FOXO6 transcriptional factor in breast carcinogenesis. Oncotarget. 2017;9(7):7464-7475doi: 10.18632/oncotarget.23779.
Lallemand, F., Petitalot, A., Vacher, S., de Koning, L., Taouis, K., Lopez, B. S., Zinn-Justin, S., Dalla-Venezia, N., Chemlali, W., Schnitzler, A., Lidereau, R., Bieche, I., & Caputo, S. M. (2018). Involvement of the FOXO6 transcriptional factor in breast carcinogenesis. Oncotarget, 9(7), 7464-7475. https://doi.org/10.18632/oncotarget.23779
Lallemand, François, et al. "Involvement of the FOXO6 transcriptional factor in breast carcinogenesis." Oncotarget vol. 9,7 (2018): 7464-7475. doi: https://doi.org/10.18632/oncotarget.23779
Lallemand F, Petitalot A, Vacher S, de Koning L, Taouis K, Lopez BS, Zinn-Justin S, Dalla-Venezia N, Chemlali W, Schnitzler A, Lidereau R, Bieche I, Caputo SM. Involvement of the FOXO6 transcriptional factor in breast carcinogenesis. Oncotarget. 2017 Dec 30;9(7):7464-7475. doi: 10.18632/oncotarget.23779. eCollection 2018 Jan 26. PMID: 29484124; PMCID: PMC5800916.
Copy Download .nbib Format: NLM
Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Nature

Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B.
PMID: 26633630
Nature. 2016 Mar 03;531(7592):126. doi: 10.1038/nature16158. Epub 2015 Dec 02.

No abstract available.

Cite
Bertolotto C, Lesueur F, Giuliano S, et al. Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2015;531(7592):126doi: 10.1038/nature16158.
Bertolotto, C., Lesueur, F., Giuliano, S., Strub, T., de Lichy, M., Bille, K., Dessen, P., d'Hayer, B., Mohamdi, H., Remenieras, A., Maubec, E., de la Fouchardière, A., Molinié, V., Vabres, P., Dalle, S., Poulalhon, N., Martin-Denavit, T., Thomas, L., Andry-Benzaquen, P., Dupin, N., Boitier, F., Rossi, A., Perrot, J. L., Labeille, B., Robert, C., Escudier, B., Caron, O., Brugières, L., Saule, S., Gardie, B., Gad, S., Richard, S., Couturier, J., Teh, B. T., Ghiorzo, P., Pastorino, L., Puig, S., Badenas, C., Olsson, H., Ingvar, C., Rouleau, E., Lidereau, R., Bahadoran, P., Vielh, P., Corda, E., Blanché, H., Zelenika, D., Galan, P., Chaudru, V., Lenoir, G. M., Lathrop, M., Davidson, I., Avril, M. F., Demenais, F., Ballotti, R., & Bressac-de Paillerets, B. (2016). Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature, 531(7592), 126. https://doi.org/10.1038/nature16158
Bertolotto, Corine, et al. "Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma." Nature vol. 531,7592 (2016): 126. doi: https://doi.org/10.1038/nature16158
Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B. Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2016 Mar 03;531(7592):126. doi: 10.1038/nature16158. Epub 2015 Dec 02. PMID: 26633630.
Copy Download .nbib Format: NLM
Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors.

Oncology reports

Champeme M, Mazoyer S, Stoppalyonnet D, Bieche I, Ithier G, Sobol H, Nogues C, Lidereau R.
PMID: 21597825
Oncol Rep. 1995 Sep;2(5):825-31. doi: 10.3892/or.2.5.825.

Frequent loss of heterozygosity (LOH) on the long arm of chromosome 17 has been described in breast tumor DNAs by a number of groups, and recent fine genetic mapping and cloning of an inherited breast-ovarian cancer susceptibility locus (BRCA1)...

Cite
Champeme M, Mazoyer S, Stoppalyonnet D, et al. Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors. Oncol Rep. 1995;2(5):825-31doi: 10.3892/or.2.5.825.
Champeme, M., Mazoyer, S., Stoppalyonnet, D., Bieche, I., Ithier, G., Sobol, H., Nogues, C., & Lidereau, R. (1995). Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors. Oncology reports, 2(5), 825-31. https://doi.org/10.3892/or.2.5.825
Champeme, M, et al. "Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors." Oncology reports vol. 2,5 (1995): 825-31. doi: https://doi.org/10.3892/or.2.5.825
Champeme M, Mazoyer S, Stoppalyonnet D, Bieche I, Ithier G, Sobol H, Nogues C, Lidereau R. Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors. Oncol Rep. 1995 Sep;2(5):825-31. doi: 10.3892/or.2.5.825. PMID: 21597825.
Copy Download .nbib Format: NLM
Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.

Human mutation

Sebai M, Tulasne D, Caputo SM, Verkarre V, Fernandes M, Reinhart F, Adams S, Maugard C, Caron O, Guillaud-Bataille M, Berthet P, Bignon YJ, Bressac-de Paillerets B, Burnichon N, Chiesa J, Giraud S, Lejeune S, Limacher JM, de Pauw A, Stoppa-Lyonnet D, Zattara-Cannoni H, Deveaux S, Lidereau R, Richard S, Rouleau E.
PMID: 34882875
Hum Mutat. 2021 Dec 09; doi: 10.1002/humu.24313. Epub 2021 Dec 09.

Hereditary papillary renal cell carcinoma (HPRC) is a rare inherited renal cancer syndrome characterized by bilateral and multifocal papillary type 1 renal tumors (PRCC1). Activating germline pathogenic variants of MET gene were identified in HPRC families. We reviewed the...

Cite
Sebai M, Tulasne D, Caputo SM, et al. Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I. Hum Mutat. 2021;doi: 10.1002/humu.24313.
Sebai, M., Tulasne, D., Caputo, S. M., Verkarre, V., Fernandes, M., Reinhart, F., Adams, S., Maugard, C., Caron, O., Guillaud-Bataille, M., Berthet, P., Bignon, Y. J., Bressac-de Paillerets, B., Burnichon, N., Chiesa, J., Giraud, S., Lejeune, S., Limacher, J. M., de Pauw, A., Stoppa-Lyonnet, D., Zattara-Cannoni, H., Deveaux, S., Lidereau, R., Richard, S., & Rouleau, E. (2021). Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I. Human mutation, . https://doi.org/10.1002/humu.24313
Sebai, Molka, et al. "Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I." Human mutation vol. (2021). doi: https://doi.org/10.1002/humu.24313
Sebai M, Tulasne D, Caputo SM, Verkarre V, Fernandes M, Reinhart F, Adams S, Maugard C, Caron O, Guillaud-Bataille M, Berthet P, Bignon YJ, Bressac-de Paillerets B, Burnichon N, Chiesa J, Giraud S, Lejeune S, Limacher JM, de Pauw A, Stoppa-Lyonnet D, Zattara-Cannoni H, Deveaux S, Lidereau R, Richard S, Rouleau E. Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I. Hum Mutat. 2021 Dec 09; doi: 10.1002/humu.24313. Epub 2021 Dec 09. PMID: 34882875.
Copy Download .nbib Format: NLM
Identification of new candidate therapeutic target genes in triple-negative breast cancer.

Genes & cancer

Glénisson M, Vacher S, Callens C, Susini A, Cizeron-Clairac G, Le Scodan R, Meseure D, Lerebours F, Spyratos F, Lidereau R, Bièche I.
PMID: 22893791
Genes Cancer. 2012 Jan;3(1):63-70. doi: 10.1177/1947601912449832.

Triple-negative breast cancer (TNBC) is a subgroup of breast cancer that is negative for estrogen and progesterone receptor and ERBB2 protein expression. It is characterized by its aggressive behavior and by the lack of targeted therapies. To identify new...

Cite
Glénisson M, Vacher S, Callens C, et al. Identification of new candidate therapeutic target genes in triple-negative breast cancer. Genes Cancer. 2012;3(1):63-70doi: 10.1177/1947601912449832.
Glénisson, M., Vacher, S., Callens, C., Susini, A., Cizeron-Clairac, G., Le Scodan, R., Meseure, D., Lerebours, F., Spyratos, F., Lidereau, R., & Bièche, I. (2012). Identification of new candidate therapeutic target genes in triple-negative breast cancer. Genes & cancer, 3(1), 63-70. https://doi.org/10.1177/1947601912449832
Glénisson, Mathilde, et al. "Identification of new candidate therapeutic target genes in triple-negative breast cancer." Genes & cancer vol. 3,1 (2012): 63-70. doi: https://doi.org/10.1177/1947601912449832
Glénisson M, Vacher S, Callens C, Susini A, Cizeron-Clairac G, Le Scodan R, Meseure D, Lerebours F, Spyratos F, Lidereau R, Bièche I. Identification of new candidate therapeutic target genes in triple-negative breast cancer. Genes Cancer. 2012 Jan;3(1):63-70. doi: 10.1177/1947601912449832. PMID: 22893791; PMCID: PMC3415670.
Copy Download .nbib Format: NLM
5' Region Large Genomic Rearrangements in the .

Cancers

Caputo SM, Telly D, Briaux A, Sesen J, Ceppi M, Bonnet F, Bourdon V, Coulet F, Castera L, Delnatte C, Hardouin A, Mazoyer S, Schultz I, Sevenet N, Uhrhammer N, Bonnet C, Tilkin-Mariamé AF, Houdayer C, Moncoutier V, Andrieu C, French Covar Group Collaborators, Bièche I, Stern MH, Stoppa-Lyonnet D, Lidereau R, Toulas C, Rouleau E.
PMID: 34202044
Cancers (Basel). 2021 Jun 25;13(13). doi: 10.3390/cancers13133171.

BACKGROUND: Large genomic rearrangements (LGR) in METHODS: DNA from 20 families with one apparent duplication and nine deletions was analyzed with a dedicated comparative genomic hybridization (CGH) array, high-resolution BRCA1 Genomic Morse Codes analysis and Sanger sequencing.RESULTS: The apparent...

Cite
Caputo SM, Telly D, Briaux A, et al. 5' Region Large Genomic Rearrangements in the . Cancers (Basel). 2021;13(13)doi: 10.3390/cancers13133171.
Caputo, S. M., Telly, D., Briaux, A., Sesen, J., Ceppi, M., Bonnet, F., Bourdon, V., Coulet, F., Castera, L., Delnatte, C., Hardouin, A., Mazoyer, S., Schultz, I., Sevenet, N., Uhrhammer, N., Bonnet, C., Tilkin-Mariamé, A. F., Houdayer, C., Moncoutier, V., Andrieu, C., French Covar Group Collaborators, Bièche, I., Stern, M. H., Stoppa-Lyonnet, D., Lidereau, R., Toulas, C., & Rouleau, E. (2021). 5' Region Large Genomic Rearrangements in the . Cancers, 13(13), . https://doi.org/10.3390/cancers13133171
Caputo, Sandrine M, et al. "5' Region Large Genomic Rearrangements in the ." Cancers vol. 13,13 (2021). doi: https://doi.org/10.3390/cancers13133171
Caputo SM, Telly D, Briaux A, Sesen J, Ceppi M, Bonnet F, Bourdon V, Coulet F, Castera L, Delnatte C, Hardouin A, Mazoyer S, Schultz I, Sevenet N, Uhrhammer N, Bonnet C, Tilkin-Mariamé AF, Houdayer C, Moncoutier V, Andrieu C, French Covar Group Collaborators, Bièche I, Stern MH, Stoppa-Lyonnet D, Lidereau R, Toulas C, Rouleau E. 5' Region Large Genomic Rearrangements in the . Cancers (Basel). 2021 Jun 25;13(13). doi: 10.3390/cancers13133171. PMID: 34202044; PMCID: PMC8268747.
Copy Download .nbib Format: NLM
Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Meseure D, Vacher S, Drak Alsibai K, Trassard M, Nicolas A, Leclere R, Lerebours F, Guinebretiere JM, Marangoni E, Lidereau R, Bieche I.
PMID: 27392414
Cancer Microenviron. 2016 Dec;9(2):107-118. doi: 10.1007/s12307-016-0186-1. Epub 2016 Jul 09.

Toll-like receptors (TLRs) are pattern recognition receptors mainly expressed by cells of the immune system but also by epithelial tumor cells. Little is known about expression patterns of TLR genes in breast tumors, and their clinical significance is unclear....

Cite
Meseure D, Vacher S, Drak Alsibai K, et al. Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes. Cancer Microenviron. 2016;9(2):107-118doi: 10.1007/s12307-016-0186-1.
Meseure, D., Vacher, S., Drak Alsibai, K., Trassard, M., Nicolas, A., Leclere, R., Lerebours, F., Guinebretiere, J. M., Marangoni, E., Lidereau, R., & Bieche, I. (2016). Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 9(2), 107-118. https://doi.org/10.1007/s12307-016-0186-1
Meseure, Didier, et al. "Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes." Cancer microenvironment : official journal of the International Cancer Microenvironment Society vol. 9,2 (2016): 107-118. doi: https://doi.org/10.1007/s12307-016-0186-1
Meseure D, Vacher S, Drak Alsibai K, Trassard M, Nicolas A, Leclere R, Lerebours F, Guinebretiere JM, Marangoni E, Lidereau R, Bieche I. Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes. Cancer Microenviron. 2016 Dec;9(2):107-118. doi: 10.1007/s12307-016-0186-1. Epub 2016 Jul 09. PMID: 27392414; PMCID: PMC5264659.
Copy Download .nbib Format: NLM
Self-other recognition impairments in individuals with schizophrenia: a new experimental paradigm using a double mirror.

NPJ schizophrenia

Keromnes G, Motillon T, Coulon N, Berthoz A, Du Boisgueheneuc F, Wehrmann M, Martin B, Thirioux B, Bonnot O, Ridereau R, Bellissant E, Drapier D, Levoyer D, Jaafari N, Tordjman S.
PMID: 30487540
NPJ Schizophr. 2018 Nov 28;4(1):24. doi: 10.1038/s41537-018-0065-5.

Clinical observations suggest early self-consciousness disturbances in schizophrenia. A double mirror combining the images of two individuals sitting on each side of the mirror was used to study self-other differentiation in 12 individuals with early onset schizophrenia (EOS) and...

Cite
Keromnes G, Motillon T, Coulon N, et al. Self-other recognition impairments in individuals with schizophrenia: a new experimental paradigm using a double mirror. NPJ Schizophr. 2018;4(1):24doi: 10.1038/s41537-018-0065-5.
Keromnes, G., Motillon, T., Coulon, N., Berthoz, A., Du Boisgueheneuc, F., Wehrmann, M., Martin, B., Thirioux, B., Bonnot, O., Ridereau, R., Bellissant, E., Drapier, D., Levoyer, D., Jaafari, N., & Tordjman, S. (2018). Self-other recognition impairments in individuals with schizophrenia: a new experimental paradigm using a double mirror. NPJ schizophrenia, 4(1), 24. https://doi.org/10.1038/s41537-018-0065-5
Keromnes, Gaelle, et al. "Self-other recognition impairments in individuals with schizophrenia: a new experimental paradigm using a double mirror." NPJ schizophrenia vol. 4,1 (2018): 24. doi: https://doi.org/10.1038/s41537-018-0065-5
Keromnes G, Motillon T, Coulon N, Berthoz A, Du Boisgueheneuc F, Wehrmann M, Martin B, Thirioux B, Bonnot O, Ridereau R, Bellissant E, Drapier D, Levoyer D, Jaafari N, Tordjman S. Self-other recognition impairments in individuals with schizophrenia: a new experimental paradigm using a double mirror. NPJ Schizophr. 2018 Nov 28;4(1):24. doi: 10.1038/s41537-018-0065-5. PMID: 30487540; PMCID: PMC6261962.
Copy Download .nbib Format: NLM
Trimodal GSTT1 and GSTM1 genotyping assay by real-time PCR.

The International journal of biological markers

Girault I, Lidereau R, Biche I.
PMID: 28207141
Int J Biol Markers. 2005 Apr - Jun;20(2):81-86. doi: 10.5301/JBM.2008.2569.

The GSTT1 and GSTM1 genes are characterized by the existence of a GST*0 null allele responsible for a lack of enzyme activity, with the respective null genotypes GSTT1*0/0 and GSTM1*0/0. The three resulting genotypes (GSTs*1/1, *1/0 and *0/0) are...

Cite
Girault I, Lidereau R, Biche I. Trimodal GSTT1 and GSTM1 genotyping assay by real-time PCR. Int J Biol Markers. 2005;20(2):81-86doi: 10.5301/JBM.2008.2569.
Girault, I., Lidereau, R., & Biche, I. (2005). Trimodal GSTT1 and GSTM1 genotyping assay by real-time PCR. The International journal of biological markers, 20(2), 81-86. https://doi.org/10.5301/JBM.2008.2569
Girault, I, et al. "Trimodal GSTT1 and GSTM1 genotyping assay by real-time PCR." The International journal of biological markers vol. 20,2 (2005): 81-86. doi: https://doi.org/10.5301/JBM.2008.2569
Girault I, Lidereau R, Biche I. Trimodal GSTT1 and GSTM1 genotyping assay by real-time PCR. Int J Biol Markers. 2005 Apr - Jun;20(2):81-86. doi: 10.5301/JBM.2008.2569. PMID: 28207141.
Copy Download .nbib Format: NLM
Allelic loss at chromosome 8p in human breast-cancer.

Oncology reports

Kerangueven F, Adelaide J, Dib A, Longy M, Lidereau R, Pebusque M, Jacquemier J, Birnbaum D.
PMID: 21607372
Oncol Rep. 1994 Mar;1(2):393-5. doi: 10.3892/or.1.2.393.

Loss of heterozygosity (LOH) at loci from the short arm of chromosome 8 has been shown to occur in several types of carcinomas. The consensus deletion region has been recently mapped at 8p21-p22, distal to D8S283 and NEFL loci,...

Cite
Kerangueven F, Adelaide J, Dib A, et al. Allelic loss at chromosome 8p in human breast-cancer. Oncol Rep. 1994;1(2):393-5doi: 10.3892/or.1.2.393.
Kerangueven, F., Adelaide, J., Dib, A., Longy, M., Lidereau, R., Pebusque, M., Jacquemier, J., & Birnbaum, D. (1994). Allelic loss at chromosome 8p in human breast-cancer. Oncology reports, 1(2), 393-5. https://doi.org/10.3892/or.1.2.393
Kerangueven, F, et al. "Allelic loss at chromosome 8p in human breast-cancer." Oncology reports vol. 1,2 (1994): 393-5. doi: https://doi.org/10.3892/or.1.2.393
Kerangueven F, Adelaide J, Dib A, Longy M, Lidereau R, Pebusque M, Jacquemier J, Birnbaum D. Allelic loss at chromosome 8p in human breast-cancer. Oncol Rep. 1994 Mar;1(2):393-5. doi: 10.3892/or.1.2.393. PMID: 21607372.
Copy Download .nbib Format: NLM
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.

Genome medicine

Callens C, Driouch K, Boulai A, Tariq Z, Comte A, Berger F, Belin L, Bièche I, Servois V, Legoix P, Bernard V, Baulande S, Chemlali W, Bidard FC, Fourchotte V, Salomon AV, Brain E, Lidereau R, Bachelot T, Saghatchian M, Campone M, Giacchetti S, Zafrani BS, Cottu P.
PMID: 33722295
Genome Med. 2021 Mar 15;13(1):44. doi: 10.1186/s13073-021-00862-6.

BACKGROUND: Prognosis evaluation of advanced breast cancer and therapeutic strategy are mostly based on clinical features of advanced disease and molecular profiling of the primary tumor. Very few studies have evaluated the impact of metastatic subtyping during the initial...

Cite
Callens C, Driouch K, Boulai A, et al. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. Genome Med. 2021;13(1):44doi: 10.1186/s13073-021-00862-6.
Callens, C., Driouch, K., Boulai, A., Tariq, Z., Comte, A., Berger, F., Belin, L., Bièche, I., Servois, V., Legoix, P., Bernard, V., Baulande, S., Chemlali, W., Bidard, F. C., Fourchotte, V., Salomon, A. V., Brain, E., Lidereau, R., Bachelot, T., Saghatchian, M., Campone, M., Giacchetti, S., Zafrani, B. S., & Cottu, P. (2021). Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. Genome medicine, 13(1), 44. https://doi.org/10.1186/s13073-021-00862-6
Callens, Céline, et al. "Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study." Genome medicine vol. 13,1 (2021): 44. doi: https://doi.org/10.1186/s13073-021-00862-6
Callens C, Driouch K, Boulai A, Tariq Z, Comte A, Berger F, Belin L, Bièche I, Servois V, Legoix P, Bernard V, Baulande S, Chemlali W, Bidard FC, Fourchotte V, Salomon AV, Brain E, Lidereau R, Bachelot T, Saghatchian M, Campone M, Giacchetti S, Zafrani BS, Cottu P. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. Genome Med. 2021 Mar 15;13(1):44. doi: 10.1186/s13073-021-00862-6. PMID: 33722295; PMCID: PMC7962302.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries